Search Results - "A. Cirstoiu-Hapca"

1

Academic Journal

Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice

Authors: Cirstoiu-Hapca, A., Buchegger, F., Lange, N., Bossy, L., Gurny, R., Delie, F.

Source: Journal of Controlled Release. Jun 01, 2010 144(3):324-331

Availability: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=00078447-201006150-00008.an

2

Academic Journal

Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells

Authors: Cirstoiu-Hapca, A., Buchegger, F., Bossy, L., Kosinski, M., Gurny, R., Delie, F.

Source: European Journal of Pharmaceutical Sciences. Oct 01, 2009 38(3):230-237

Availability: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=00019515-200910080-00006.an

3

Academic Journal

Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles

Authors: Cirstoiu-Hapca, A., Bossy-Nobs, L., Buchegger, F., Gurny, R., Delie, F.

Source: International Journal of Pharmaceutics. Mar 01, 2006 331(2):190-196

Availability: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=00009602-200603130-00009.an

4

Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice

Authors: Franz Buchegger, Leila Bossy, Florence Delie, A. Cirstoiu-Hapca, Robert Gurny, Norbert Lange

Source: Journal of Controlled Release, Vol. 144, No 3 (2010) pp. 324-331

Subject Terms: Pharmaceutical Science, Cancer, medicine.disease, medicine, Monoclonal, Pharmacokinetics, Drug carrier, Biodistribution, Ovarian cancer, Bioluminescence imaging, Pharmacology, Pathology, medicine.medical_specialty, Paclitaxel, chemistry.chemical_compound, chemistry, business.industry, business, ddc:615, ddc:616.0757, Animals, Antibodies, Monoclonal/administration & dosage/pharmacokinetics/*therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phytogenic/administration & dosage/pharmacokinetics/*therapeutic use, Cell Line, Tumor, Drug Carriers/*chemistry, Female, Humans, Mice, Nanoparticles/*chemistry, Ovarian Neoplasms/*drug therapy, Paclitaxel/administration & dosage/pharmacokinetics/*therapeutic use, Receptor, erbB-2/*immunology, Tissue Distribution, Xenograft Model Antitumor Assays

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9620b209f7ff4301c1defc186207bbe
https://doi.org/10.1016/j.jconrel.2010.02.026

5

Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells

Authors: Leila Bossy, Florence Delie, Marek Kosinski, Franz Buchegger, Robert Gurny, A. Cirstoiu-Hapca

Source: European Journal of Pharmaceutical Sciences. 38:230-237

Subject Terms: Pharmaceutical Science, Pharmacology, In vitro, Antigen, Molecular biology, Monoclonal, Cytotoxic T cell, Paclitaxel, chemistry.chemical_compound, chemistry, Monoclonal antibody, medicine.drug_class, medicine, Zeta potential, Drug carrier, technology, industry, and agriculture

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_________::d4e118f05563f04085642fccaf11de38
https://doi.org/10.1016/j.ejps.2009.07.006

6

Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles

Authors: Leila Bossy-Nobs, A. Cirstoiu-Hapca, Florence Delie, Robert Gurny, Franz Buchegger

Source: International Journal of Pharmaceutics, Vol. 331, No 2 (2007) pp. 190-6

Subject Terms: Pharmaceutical Science, Microparticle, Bifunctional, chemistry.chemical_compound, chemistry, Monoclonal antibody, medicine.drug_class, medicine, Cell culture, Antigen, Stereochemistry, Cystamine, Antibody-dependent cell-mediated cytotoxicity, Biophysics, Carbodiimide, technology, industry, and agriculture, respiratory system, health care economics and organizations, inorganic chemicals, education, ddc:615, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal, Murine-Derived, Antigens, CD20/immunology, Antineoplastic Agents/administration & dosage/chemistry, Cell Line, Tumor, Cross-Linking Reagents, Drug Carriers/chemistry, Drug Delivery Systems/methods, Female, Humans, Immunoconjugates/chemistry, Lactic Acid, Lymphoma/drug therapy, Nanoparticles/chemistry/therapeutic use, Ovarian Neoplasms/drug therapy, Polymers, Receptor, erbB-2/immunology, Sulfhydryl Compounds

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc46f7a49e502ee5ad0abb222538797d
https://doi.org/10.1016/j.ijpharm.2006.12.002

7

Academic Journal

Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.

Authors: Cirstoiu-Hapca A; Department of Pharmaceutics and Biopharmaceutics, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland., Bossy-Nobs L, Buchegger F, Gurny R, Delie F

Source: International journal of pharmaceutics [Int J Pharm] 2007 Mar 01; Vol. 331 (2), pp. 190-6. Date of Electronic Publication: 2006 Dec 15.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0378-5173 (Print) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE